Dr. Daigle graduated from the Louisiana State University School of Medicine at Shreveport in 1990. He works in Seattle, WA and specializes in Family Medicine. Dr. Daigle is affiliated with VA Puget Sound Healthcare Seattle Division.
Edward James Olhava - Newton MA, US Richard Chesworth - Boston MA, US Kevin Wayne Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy Macfarlane Pollock - Medford MA, US Scott Richard Daigle - Newburyport MA, US
Assignee:
Epizyme, Inc. - Cambridge MA
International Classification:
A61K 31/70 C07H 19/00
US Classification:
514 46, 536 276
Abstract:
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Richard Chesworth - Concord MA, US Kevin W. Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy M. Pollock - Medford MA, US Scott R. Daigle - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/7076 A61K 31/52
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott R. DAIGLE - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/7076 A61K 31/52
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin Wayne KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott R. DAIGLE - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard Chesworth - Concord MA, US Kevin W. Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy M. Pollock - Medford MA, US Scott Richard Daigle - Newburyport MA, US
International Classification:
A61K 31/7076
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
License Records
Scott W. Daigle
License #:
CPT.004296 - Expired
Issued Date:
Feb 3, 2000
Expiration Date:
Jun 30, 2003
Type:
Certified Pharmacy Technician
Googleplus
Scott Daigle
Work:
Kamco Supply Corp. of New England - Project Manager
Education:
Rensselaer Polytechnic Institute - Management
Tagline:
Keywest Florida, 2009
Scott Daigle
Work:
InelliWheels, Inc. - Co-Founder / CEO (2010)
Education:
University of Illinois at Urbana-Champaign - Mechanical Engineering
Scott Daigle
Work:
Sikorsky Aircraft - Electrical QA
Education:
Central Connecticut State University - Communication
Scott Daigle
Scott Daigle
Scott Daigle
Scott Daigle
Scott Daigle
Youtube
Scott Daigle's invention at the University of...
Scott Daigle, a graduate student in the Department of Mechanical Scien...
Duration:
3m 11s
Meet Scott Daigle at Community Toyota!
Stop by or shop CommunityToyota....
Duration:
11s
Ready For College with Scott Daigle, M.Ed.
G Star High School of the Arts PTO is proud to partner with Premier Co...
Duration:
47m 24s
Hillary Scott & The Scott Family - Thy Will (...
Music video by Hillary Scott & The Scott Family performing Thy Will. (...
de-escalation techniques to handle situations that get out of control in emergency rooms. A revised version of the bill would make allowances for people with mental illness, dementia or developmental disabilities be exempt from enhanced penalties, said Howards chief of staff, Scott Daigle. SB 36